PMC6174736_01
Development in BCR-ABL1/ABL1 transcript levels in the setting of relapsed CML. The figure shows the BCR-ABL1/ABL1 transcript levels in peripheral blood for the patient. Time point 0 represents the diagnosis of CML relapse and initiating of imatinib therapy.
CRIHEM2018-2045985.001.jpg
PMC6174736_01_CRIHEM2018-2045985.001.jpg
fig1
Her transcript levels then suddenly increased rapidly, and she lost her MR (Figure 1). She tolerated the treatment well without major side effects; after three months, she obtained MR4 status (Figure 1), and imatinib treatment was continued with regular monitoring of BCR-ABL1 quantitative RT-PCR.